Hematology
4 drugs are in development for Myelofibrosis.
- Companies
- 4
- Clinical trials
- 39
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Myelofibrosis pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| momelotinib | Sierra Oncology, Inc. (SRRA) |
Phase 2(1)
| Drug | Company |
|---|---|
| gb2064 | Damora Therapeutics, Inc. (DMRA) |
Preclinical(1)
| Drug | Company |
|---|---|
| morf-088 | Morphic Holding, Inc. (MORF) |
Phase 1/Phase 2(1)
About this indication
Myelofibrosis context
Hematology·MeSH: Primary Myelofibrosis (D055728)
Also known as: Agnogenic Myeloid Metaplasias, Bone Marrow Fibroses, Bone Marrow Fibrosis, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, Metaplasia, Agnogenic Myeloid, Metaplasia, Myeloid, Metaplasias, Myeloid, Myelofibroses, Myelofibroses, Primary, Myelofibrosis With Myeloid Metaplasia, Myelofibrosis, Primary, Myeloscleroses, Myelosclerosis, Myeloses, Nonleukemic, Nonleukemic Myelosis
Compare drugs
Frequently asked questions
How many drugs are in development for Myelofibrosis?
BioSniper tracks 4 drugs in development for Myelofibrosis across 4 companies.
How many clinical trials target Myelofibrosis?
There are 39 clinical trials targeting Myelofibrosis tracked by BioSniper.